Project Grant R01HL178514
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $759,210 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective April 1, 2026, with a completion date of January 31, 2031. This grant supports translational research investigating the impact of prenatal tetrahydrocannabinol (THC) exposure on offspring neurodevelopment and behavioral outcomes. The research leverages a...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $737,378 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on June 5, 2026, with a completion date of March 31, 2031. This award funds a longitudinal follow-up study of preterm infants from a completed randomized controlled trial examining extended continuous positive airway pressure (ECPAP) therapy in the...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $1.489 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 1, 2025, with completion targeted for May 31, 2030. This translational research project aims to identify and validate fetal central nervous system-derived extracellular vesicles (CNSEVs) as biomarkers for predicting neurodevelopmental...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded Tulane University $2.66 million under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the impact of chronic prenatal tetrahydrocannabinol (THC) exposure on simian immunodeficiency virus (SIV)-associated inflammation and fetal development. The research addresses a critical gap in understanding how cannabis use compounds pregnancy complications among pregnant individuals with HIV who are receiving...
- Federal Grant Award Summary Oregon Health & Science University received a $905,044 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning May 1, 2026, and concluding April 30, 2028. This two-year mixed-methods research study will examine current assessment and documentation practices of electronic nicotine delivery systems (ENDS) use in primary care settings across 22 clinics serving over 154,000 patients. The...
- Federal Grant Award Summary Oregon Health & Science University received a $1,512,345 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective August 1, 2025, through April 30, 2030. The research investigates placental essential fatty acid (EFA) metabolism in gestational diabetes mellitus (GDM) using integrative spatial multiomics approaches. The project...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $234,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion scheduled for August 31, 2027. The project investigates the impact of SARS-CoV-2 on human herpesvirus co-infections, with a specific focus on identifying biomarkers associated with Long COVID and herpesvirus...
- Federal Grant Award Summary Washington State University received a $639,915 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded February 15, 2026, with a completion date of December 31, 2030. This research initiative investigates the mechanistic underpinnings of cognitive inflexibility in offspring exposed to prenatal cannabis. The project employs a novel, translationally relevant animal model utilizing cannabis...
- Federal Project Grant Award Summary Oregon Health & Science University received a $746,208 Project Grant award from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective June 1, 2026, through February 28, 2031. The award supports research investigating the role of the corpus luteum on placental development, specifically examining adverse pregnancy outcomes associated with programmed...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $1.87 million project grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 30, 2025, with completion targeted for May 31, 2030. The project conducts basic neuroscience research investigating thyroid hormone-mediated reprogramming of the basolateral amygdala (BLA) in response to adolescent social deprivation. The research...
Oregon Health & Science University received a $852,908 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) effective July 1, 2026, with a completion date of March 31, 2030. The award funds a research project investigating the effects of prenatal tetrahydrocannabinol (THC) exposure on offspring lung development and function. The research addresses a critical knowledge gap regarding respiratory health outcomes in infants exposed to cannabis during pregnancy, leveraging non-human primate models to provide mechanistic insights with direct translation to human health outcomes. The project will generate scientific research products including mechanistic data on how prenatal THC exposure affects fetal and infant lung development, transcriptional and epigenetic analysis of affected lung tissue, and functional respiratory assessments of exposed offspring. The research will produce peer-reviewed publications and technical findings that advance understanding of how cannabinoid receptor signaling during critical developmental windows impacts offspring pulmonary structure and gas exchange capacity. These deliverables will inform clinical safety guidance regarding cannabis use during pregnancy and contribute to evidence-based recommendations for pregnant individuals and healthcare providers.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $852.9k | 6/9/26 |